about
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesisA validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia.Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells.Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia.Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone.PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy.MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsIGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cellsReal-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvestsTelomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disordersHigh-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remissionTelomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients
P50
Q24654905-57FAC0E1-D56D-44EB-9E1B-5A452CE973B0Q31883517-5BEE2AF2-E146-4F57-97A7-4139944DBE3DQ34973576-CE08F014-845D-42A1-B35D-94C58802C486Q35759705-FCD18DCD-92A1-4734-B9E2-0960CCCB3623Q36557448-8A03DF80-B48C-4BE4-9145-669F0C61B96CQ37701511-7801EFC4-FA16-4C93-BF2B-66129F926D64Q37709461-B5A4D63E-314E-4131-8689-E37ADB9AD1DFQ40443044-05BCF7BD-793A-477D-AEE8-341C0D32D020Q42120007-677FAB3F-8829-41BC-9915-05F5B33EFFADQ42336329-135A0715-C156-4082-93B0-10167AB68B32Q43837244-C283A1E1-D127-4618-8CEF-EDF319E81A06Q45202285-ECEA9835-5307-460D-A6B8-B043FB28840CQ45785426-D25023BE-1363-4822-8085-AADB83C55900Q47367539-C93314BC-008E-44E3-BDC2-34E8ABCA9E96Q47433684-EE8B4E7F-24B0-46D1-9525-5EE7E9D49885Q48335780-15505F65-1E17-459D-8612-505E782991B7Q51548976-464FB091-EEB5-4ACF-9A9A-CA9D2529C624Q52912068-AE791967-4C6A-40B7-A578-A96210464849Q53163477-58FE45D3-23B4-4F15-B592-A9673ACACC1FQ54567794-DD3C09C4-0C8B-4AC3-8808-5D7F6EEC0F95Q54568188-996D909C-C4A8-4BA7-83BA-9B4E8F340B50Q54756122-C50D7191-40EB-44C4-8406-6EE568C9BC34Q54781668-1EB697DE-9263-44FE-A052-B1A8394F5444Q58164582-36BB67F1-DB34-45D2-A233-D743EEE60623Q60617037-6ABE1111-8D64-4E08-AC5F-7C0710F5A94DQ74293894-1722CB98-312F-4984-B1E3-D8E273E6306FQ76385398-1A49C5B0-A772-45A2-8550-602396C84FB4Q79182827-4CD5E924-EFC2-4809-AF82-AB592DCAAF41Q79777424-B4F7A07F-50D1-4293-A7CF-CA6E58C1E68D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniela Drandi
@ast
Daniela Drandi
@en
Daniela Drandi
@es
Daniela Drandi
@nl
type
label
Daniela Drandi
@ast
Daniela Drandi
@en
Daniela Drandi
@es
Daniela Drandi
@nl
prefLabel
Daniela Drandi
@ast
Daniela Drandi
@en
Daniela Drandi
@es
Daniela Drandi
@nl
P106
P1153
6507870084
P21
P31
P496
0000-0003-1825-1206